Modality
Peptide
MOA
CDK4/6i
Target
EZH2
Pathway
Innate Imm
T2D
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
~Feb 2018
→ ~May 2019
Phase 3
Aug 2019
→ Jul 2031
Phase 3Current
NCT08502349
1,329 pts·T2D
2019-11→2031-07·Completed
NCT03471256
75 pts·T2D
2019-08→2029-05·Recruiting
1,404 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-05-183.1y awayPh3 Readout· T2D
2031-07-055.3y awayPh3 Readout· T2D
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2029-05-18 · 3.1y away
T2D
Ph3 Readout
2031-07-05 · 5.3y away
T2D
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08502349 | Phase 3 | T2D | Completed | 1329 | BodyWt |
| NCT03471256 | Phase 3 | T2D | Recruiting | 75 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ |